- Home
- FNLC vs CRDF Comparison
FNLC vs CRDF Comparison
Compare FNLC & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FNLC | CRDF |
|---|---|---|
| Founded | 1864 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.7M | 142.1M |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | FNLC | CRDF |
|---|---|---|
| Price | $27.11 | $3.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.83 |
| AVG Volume (30 Days) | 20.3K | ★ 1.0M |
| Earning Date | 01-21-2026 | 11-06-2025 |
| Dividend Yield | ★ 5.51% | N/A |
| EPS Growth | ★ 18.07 | N/A |
| EPS | ★ 2.81 | N/A |
| Revenue | ★ $88,119,000.00 | $501,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.55 | ★ N/A |
| Revenue Growth | ★ 12.70 | N/A |
| 52 Week Low | $22.11 | $1.90 |
| 52 Week High | $28.60 | $4.99 |
Technical Indicators
Market Signals| Indicator | FNLC | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 51.35 | 81.65 |
| Support Level | $28.05 | $2.32 |
| Resistance Level | $28.60 | $2.95 |
| Average True Range (ATR) | 0.51 | 0.18 |
| MACD | -0.10 | 0.09 |
| Stochastic Oscillator | 34.21 | 92.50 |
Price Performance
Historical ComparisonAbout FNLC First Bancorp Inc (ME)
First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.